N-Acetylcysteine to Combat COVID-19: An Evidence Review

References

• Jamwal S, Gautam A, Elsworth J, et al. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life Sci. 2020;257:118105. doi:10.1016/j.lfs.2020.118105
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Huang KJ, Su IJ, Theron M, et al. An interferon-γ-related cytokine storm in SARS patients. J Med Virol. 2005;75:185–194. doi:10.1002/jmv.20255
   PubMed Web of Science ®Google Scholar
• Stegelmeier AA, van Vloten JP, Mould RC, et al. Myeloid Cells during Viral Infections and Inflammation. Viruses. 2019;11(2):168. doi:10.3390/v11020168
   PubMed Web of Science ®Google Scholar
• Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell. 2020;182(6):1419–1440. doi:10.1016/j.cell.2020.08.001
   PubMed Web of Science ®Google Scholar
• Janoff A. Elastase in tissue injury. Ann Rev Med. 1985;36:207–216. doi:10.1146/annurev.me.36.020185.001231
   PubMed Web of Science ®Google Scholar
• Thierry AR. Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19. Physiol Rev. 2020;100(4):1597–1598. doi:10.1152/physrev.00019.2020
   PubMed Web of Science ®Google Scholar
• Cruz DB, Helms J, Aquino LR, et al. DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma. FASEB J. 2020. doi:10.1096/fj.201901363RRR
   Web of Science ®Google Scholar
• Leonard-Lorant I, Delabranche X, Severac F, et al. Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels. Radiology. 2020;296(3):E189–E191. doi:10.1148/radiol.2020201561
   PubMed Web of Science ®Google Scholar
• Xu J, Wang L, Zhao L, et al. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients. Res Square. 2020. doi:10.21203/rs.3.rs-18340/v1
   Google Scholar
• Mukaida N, Matsumoto T, Yokoi K, et al. Inhibition of neutrophil-mediated acute inflammatory injury by an antibody against interleukin-8 (IL-8). Inflammation Res. 1998;47:151–157. doi:10.1007/s000110050308
   Web of Science ®Google Scholar
• Bao Z, Ye Q, Gong W, et al. Humanized monoclonal antibody against the chemokine CXCL-8 (IL-8) effectively prevents acute lung injury. Int Immunopharmacol. 2010;10(2):259–263. doi:10.1016/j.intimp.2009.11.005
   PubMed Web of Science ®Google Scholar
• Wayne SJ, Rhyne RL, Garry PJ, et al. Cell-Mediated Immunity as a Predictor of Morbidity and Mortality in Subjects Over 60. J Gerontol. 1990;45(2):45–48. doi:10.1093/geronj/45.2.M45
   Google Scholar
• Ohrui T. Interventions to prevent pneumonia in older adults. Geriatr Gerontol Int. 2004;4(s1):92–95. doi:10.1111/j.1447-0594.2004.00162.x
   Google Scholar
• Saule P, Trauet J, Dutriez V, et al. Accumulation of memory T cells from childhood to old age, Central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. Mech Ageing Dev. 2006;127(3):274–281. doi:10.1016/j.mad.2005.11.001
   PubMed Web of Science ®Google Scholar
• Li H, Wang S, Zhong F, et al. Age-dependent risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China. Fron Med. 2015:214. doi:10.3389/fmed.2020.00190
   Web of Science ®Google Scholar
• Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv. 2020. doi:10.1101/2020.03.12.20035048
   Google Scholar
• Ma Y, Shi N, Fan Y, et al. Predictive Value of the Neutrophil-to-Lymphocyte Ratio (NLR) for diagnosis and worse clinical course of the COVID-19: findings from ten provinces in China. Lancet. 2020. doi:10.2139/ssrn.3569838
   Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2015;14:148. doi:10.1093/cid/ciaa248
   Web of Science ®Google Scholar
• Zhu F, Li Y, Guan X, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020. doi:10.1016/S0140-6736(20)31208-3
   PubMed Web of Science ®Google Scholar
• Flora SD, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respiratory J. 1997;10(7):1535–1541. doi:10.1183/09031936.97.10071535
   PubMed Web of Science ®Google Scholar
• Poppe M, Wittig S, Jurida L, et al. The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. PLoS Pathog. 2017;13(3):e1006286. doi:10.1371/journal.ppat.1006286
   PubMed Web of Science ®Google Scholar
• Geiler J, Michaelis M, Naczk P, et al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010;79(3):413–420. doi:10.1016/j.bcp.2009.08.025
   PubMed Web of Science ®Google Scholar
• Ho W, Douglas SD. Glutathione and N-Acetylcysteine suppression of human immunodeficiency virus replication in human Monocyte/Macrophages in vitro. AIDS Res Hum Retroviruses. 1992;8(7):1249–1253. doi:10.1089/aid.1992.8.1249
   PubMed Web of Science ®Google Scholar
• Mata M, Sarrion I, Armengot M, et al. Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-Acetylcysteine. PLoS One. 2012;7(10):e48037. doi:10.1371/journal.pone.0048037
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368:409–412.
   PubMed Web of Science ®Google Scholar
• Guthappa R. Molecular Docking Studies of N-Acetyl Cysteine, Zinc Acetyl Cysteine and Niclosamide on SARS Cov 2 Protease and Its Comparison with Hydroxychloroquine. Chemarxiv. 2020. doi:10.26434/chemrxiv.12161493.v1
   Google Scholar
• Sadowskaa AM, Manuel-y-Keenoy B, Vertongen T, et al. Effect of N-acetylcysteine on neutrophil activation markers in healthy volunteers: in vivo and in vitro study. Pharmacol Res. 2006;53(3):216–225. doi:10.1016/j.phrs.2005.11.003
   PubMed Web of Science ®Google Scholar
• Kharazmi A. Nielsen H and Schiotx PO. N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Lmmunopharmac. 1988;10(1):39–46. doi:10.1016/0192-0561(88)90148-8
   PubMed Web of Science ®Google Scholar
• Allegra L, Sasso MD, Bovio C, et al. Human Neutrophil Oxidative Bursts and their in vitro Modulation by Different N-Acetylcysteine Concentrations. Drug Res. 2002;52(9):669–676.
   Web of Science ®Google Scholar
• Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia during the COVID-19 infection: what it shows and what can be learned. Immunol Lett. 2020;225:31–32. doi:10.1016/j.imlet.2020.06.013
   PubMed Web of Science ®Google Scholar
• Chiba T, Takahashi S, Sato N, et al. Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells. Eur J Immunol. 1996;26(5):1164–1169. doi:10.1002/eji.1830260530
   PubMed Web of Science ®Google Scholar
• Lai Z, Hanczko R, Bonilla E, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial. Arthritis Rheumatology. 2012;64(9):2937–2946. doi:10.1002/art.34502
   PubMed Web of Science ®Google Scholar
• Sharafkhah M, Abdolrazaghnejad A, Zarinfar N, et al. Safety and efficacy of N-acetylcysteine for prophylaxis of ventilator-associated pneumonia: a randomized, double blind, placebo-controlled clinical trial. Mojtaba Med Gas Res. 2018;8(1):19–23. doi:10.4103/2045-9912.229599
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ju Y, Ma Y, et al. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia A randomized controlled trial. Medicine. 2018;97:e13087.
   PubMed Web of Science ®Google Scholar
• Ragab D, Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; What we know so far. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01446
   Web of Science ®Google Scholar
• Hassett P, Curley GF, Contreras M, et al. Overexpression of pulmonary extracellular superoxide dismutase attenuates endotoxin induced acute lung injury. Intensive Care Med. 2011;37:1680–1687.
   PubMed Web of Science ®Google Scholar
• Fox RB. Prevention of granulocyte-mediated oxidant lung injury in rats by a hydroxyl radical scavenger, dimethylthiourea. J Clin Invest. 1984;74(4):1456–1464. doi:10.1172/JCI111558
   PubMed Web of Science ®Google Scholar
• Li L, Huang Q, Wang DC, et al. Acute lung injury in patients with COVID-19 infection. Clin Transl Med. 2020. doi:10.1002/ctm2.16
   Web of Science ®Google Scholar
• Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593–597. doi:10.1016/0891-5849(89)90066-X
   PubMed Web of Science ®Google Scholar
• Suter PM, Domenighetti G, Schaller MD, et al. N-Acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105(1):190–194. doi:10.1378/chest.105.1.190
   PubMed Web of Science ®Google Scholar
• Lai K, Ng W, Chan PK, et al. High-Dose N-Acetylcysteine Therapy for Novel H1N1 Influenza Pneumonia. Ann Intern Med. 2010;152(10):687. doi:10.7326/0003-4819-152-10-201005180-00017
   PubMed Web of Science ®Google Scholar
• Moradi M, Mojtahedzadeh M, Mandegari A, et al. The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. Respir Med. 2009;103(3):434–441. doi:10.1016/j.rmed.2008.09.013
   PubMed Web of Science ®Google Scholar
• Puyo C, Kreig D, Saddi V, et al. Case Report: use of hydroxychloroquine and N-acetylcysteine for treatment of a COVID-19 positive patient [version 1; peer review: awaiting peer review]. F1000Research. 2020;9:491.
   Google Scholar
• Liu Y, Luo G, Qian X, et al. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19. Researchsquare. 2020. doi:10.21203/rs.3.rs-34193/v1
   Google Scholar
• Nasia A, McArdleb S, Gaudernackc G, et al. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. Toxicol Rep. 2020;7:768–771. doi:10.1016/j.toxrep.2020.06.003
   PubMed Web of Science ®Google Scholar
• Ibrahim H, Perl A, Smith D, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine. Clin Immunol. 2020;219:108544. doi:10.1016/j.clim.2020.108544
   PubMed Web of Science ®Google Scholar
• ACETADOTE® (acetylcysteine) Injection. NDA 21-539/S-004. FDA. 2006
   Google Scholar
• Dósa E, Helta K, Radovits T, et al. Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency. Fluids and Barriers of the CNS. 2017;14(1):26. doi:10.1186/s12987-017-0075-0
   PubMed Web of Science ®Google Scholar
• Hong SY, Gil HW, Yang JO, et al. Effect of High-Dose Intravenous N-acetylcysteine on the Concentration of Plasma Sulfur-Containing Amino Acids. Korean J Intern Med. 2005;20:217–223. doi:10.3904/kjim.2005.20.3.217
   PubMedGoogle Scholar
• MacDonald TT. The gut is still the biggest lymphoid organ in the body. Nature. 2008;1(4):246–247.
   Google Scholar
• Green JL, Heard KJ, Reynolds KM, et al. Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis. West J Emerg Med. 2013;14(3):218–226. doi:10.5811/westjem.2012.4.6885
   PubMedGoogle Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. NEJM. 2020;382(24):2327–2336. doi:10.1056/NEJMoa2007016
   PubMed Web of Science ®Google Scholar
• Yazdi AP, Razavi M, Sheikh S, et al. Clinical Trial Assessment of Intermittent and Continuous Infusion Dose of N-Acetylcysteine on Redox Status of the Body in Patients with Sepsis Admitted to the ICU. J Intensive Care Med. 2019. doi:10.1177/0885066618823152
   Web of Science ®Google Scholar
• Molnar Z, Shearer E, Lowe D, et al. N-Acetylcysteine treatment to prevent the progression of multisystem organ failure: a prospective, randomized, placebo-controlled study. Crit Care Med. 1999;27(6):1100–1104. doi:10.1097/00003246-199906000-00028
   PubMed Web of Science ®Google Scholar